Biochemical Engineering Special Interest Group
biological engineering professionals
15 June 2017

LifeArc to invest Keytruda Royalties

More than a decade ago, a UK charity, MRC Technology, the technology commercialization arm of the UK Medical Research Council (MRC), helped Merck & Co. (MRK) develop its immuno-oncology drug Keytruda (pembrolizumab). MRC Technology recently changed its name to LifeArc, and intends to use the approximately $636 million in royalties it receives from Merck to invest in research and new therapies. Source: Biospace 15/6/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).